Treatment traps in restless legs syndrome

Dr Linda Calabresi

writer

Dr Linda Calabresi

GP; Medical Editor, Healthed

Dr Linda Calabresi

 

One of the most common treatments for restless legs syndrome can, in about a third of cases, wind up making the symptoms worse, warns respiratory and sleep physician Professor Brendon Yee from Sydney.

Dopaminergic therapy including dopamine agonists such as pramipexole (Sifrol) is widely used in people with severe restless legs syndrome and it is highly effective, working in about 80% of cases, Professor Yee said on a recent Healthed podcast.

PASSWORD RESET

Forgot your password or password not working? Please enter your email address. You will receive an email with the link to set a new password.

Further your CPD learning

Based on this educational activity, complete these learning modules to gain additional CPD.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Rod Baber

Prof Rod Baber

Menopause and MHT: Maximising Benefits & Minimising Risks

Dr Fiona Chan

Dr Fiona Chan

Multiple Sclerosis vs Antibody Disease – What GPs Need to Know

Prof Andrew Sindone & Dr Ted Wu

Prof Andrew Sindone & Dr Ted Wu

Using SGLT2 to Reduce Cardiovascular Death in T2D – Important Updates for GPs

Dr Shannon Thomas

Dr Shannon Thomas

Peripheral Arterial Disease

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Dr Linda Calabresi

writer

Dr Linda Calabresi

GP; Medical Editor, Healthed

Test your knowledge

Recent articles

Latest GP poll

Has a clinic you work at ever received an unfair negative online review?

Yes

0%

No

0%

Recent podcasts

Listen to expert interviews.
Click to open in a new tab

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Menopause and MHT

Multiple sclerosis vs antibody disease

Using SGLT2 to reduce cardiovascular death in T2D

Peripheral arterial disease